Comparative evaluation of authorized drugs for treating Covid‐19 patients

Comparative evaluation of authorized drugs for treating Covid‐19 patients

Abstract Background and Aims Vaccines are the first line of defense against coronavirus disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid‐19 pandemic. Here we aimed for a comparative evaluation of authorized drugs for treating Covid‐19 patients. Methods We s...

Full description

Bibliographic Details
Main Authors:	Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, Md. Rabiul Islam
Format:	Article
Language:	English
Published:	Wiley 2022-07-01
Series:	Health Science Reports
Subjects:	antivirals Covid‐19 dexamethasone molnupiravir monoclonal antibody paxlovid
Online Access:	https://doi.org/10.1002/hsr2.671

Similar Items

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
by: Wen Wen, et al.
Published: (2022-12-01)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
by: Éva Bakos, et al.
Published: (2023-07-01)

Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
by: Ling Ye, et al.
Published: (2023-09-01)

Thymoquinone’s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
by: Maen Abdelrahim, et al.
Published: (2022-04-01)

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
by: Ashour NA, et al.
Published: (2022-03-01)

Absolute Risk Reductions in COVID-19 Antiviral Medication Clinical Trials
by: Ronald B. Brown
Published: (2023-03-01)

Does ivermectin have a place in the treatment of mild Covid-19?
by: Eli Schwartz
Published: (2022-03-01)

Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo
by: Yuexiang Li, et al.
Published: (2022-05-01)

Mild COVID- 19 infection: Do we have any effective drugs? A narrative review
by: Deependra K Rai, et al.
Published: (2022-01-01)

Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks
by: Tommaso Manciulli, et al.
Published: (2022-04-01)

A Community Pharmacist’s Guide to Oral COVID-19 Antivirals
by: Tyler C. Melton, et al.
Published: (2022-10-01)

[Translated article] Practical Guide to New Treatments for SARS-CoV-2 Infection in Dermatology Patients Being Treated With Common Immunomodulators
by: M. Viedma-Martínez, et al.
Published: (2023-01-01)

Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
by: Carsten Schade Larsen
Published: (2022-09-01)

Antiviral therapy of coronavirus disease 2019 (COVID-19)
by: Pao-Yu Chen, et al.
Published: (2024-01-01)

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
by: Julie M. Strizki, et al.
Published: (2023-11-01)

Guía práctica de las nuevas alternativas terapéuticas frente a SARS-CoV-2 en pacientes con inmunomoduladores de uso frecuente en dermatología
by: M. Viedma-Martínez, et al.
Published: (2023-01-01)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
by: Yuan Bai, et al.
Published: (2022-04-01)

Update on COVID-19 Therapy in Pediatric Age
by: Susanna Esposito, et al.
Published: (2022-12-01)

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro
by: Zi-Xin Huang, et al.
Published: (2023-06-01)

Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor
by: Alireza Pouramini, et al.
Published: (2022-07-01)

Investigational Drugs for the COVID 19 Pandemic – A Concise Review
by: Reena Sherin Parveen, et al.
Published: (2020-11-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections
by: Tibor Bakacs, et al.
Published: (2022-10-01)

Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
by: Giuseppe Bruno, et al.
Published: (2022-11-01)

Molnupiravir; an effective drug in treating COVID-19?
by: Alireza Pouramini, et al.
Published: (2022-01-01)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
by: Ioannis Karniadakis, et al.
Published: (2023-10-01)

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and FutunaResearch in context
by: Antoine Brault, et al.
Published: (2023-01-01)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
by: Ashley Jia Wen Yip, et al.
Published: (2022-06-01)

Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use
by: Cosmo Del Borgo, et al.
Published: (2023-04-01)

Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry
by: Tommaso Lupia, et al.
Published: (2022-11-01)

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
by: Rana Abdelnabi, et al.
Published: (2021-10-01)

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
by: Henrik Berg Rasmussen, et al.
Published: (2023-10-01)

Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study
by: Mykhailo Buchynskyi, et al.
Published: (2024-01-01)

Molnupiravir and Its Antiviral Activity Against COVID-19
by: Lili Tian, et al.
Published: (2022-04-01)

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
by: Ching-Chi Lee, et al.
Published: (2021-10-01)

Safety and Effectiveness of Molnupiravir in Covid-19 Treatment: A Rapid Review
by: Mohammadreza Mobinizadeh, et al.
Published: (2022-10-01)

Early Treatments of Fragile Children with COVID-19—Results of CLEVER (Children COVID Early Treatment), a Retrospective, Observational Study
by: Chiara Minotti, et al.
Published: (2023-01-01)

COVID-19 rebound after oral treatment in a nursing home facility: A case series
by: Alex P. Betrosian, et al.
Published: (2022-12-01)

Identifying Innate Resistance Hotspots for SARS-CoV-2 Antivirals Using In Silico Protein Techniques
by: Stephanie Portelli, et al.
Published: (2023-08-01)

Real-World Use of Molnupiravir in the Treatment of Outpatients with SARS-CoV-2 Infection—A Patient Profile Based on the Experience of a Tertiary Infectious Disease Center
by: Anca Streinu-Cercel, et al.
Published: (2022-08-01)